UK Markets closed

Biodesix, Inc. (BDSX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.4800-0.1300 (-8.07%)
At close: 04:00PM EDT

Biodesix, Inc.

2970 Wilderness Place
Suite 100
Boulder, CO 80301
United States
303 417 0500
https://www.biodesix.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees218

Key executives

NameTitlePayExercisedYear born
Mr. Scott HuttonPres, CEO & Director586.3kN/A1972
Ms. Robin Harper CowieCFO, Sec. & Treasurer349.05kN/A1980
Mr. Ryan H. SiurekChief Accounting Officer294.87kN/A1972
Dr. Heinrich RöderFounder & CTON/AN/AN/A
Mr. Robert E. CawthornFounder & Director EmeritusN/AN/A1935
Dr. Robert W. Georgantas III, Ph.D.Chief Scientific OfficerN/AN/A1971
Mr. Jeffrey A. BojarVP of Legal and Regulatory AffairsN/AN/AN/A
Mr. Matt StaufferVP of SalesN/AN/AN/A
Dr. Paul J. BeresfordChief Bus. OfficerN/AN/AN/A
Dr. Gary Anthony Pestano Ph.D.Chief Devel. OfficerN/AN/A1967
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Corporate governance

Biodesix, Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.